At 2022 ASCO GU, Daniel M. Geynisman, MD, spoke with CancerNetwork® about his strategy for treating renal cell carcinoma across lines of therapy.
Daniel M. Geynisman, MD
Advertisement
Articles by Daniel M. Geynisman, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
2
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
3
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
4
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
5
